491 results
8-K
DMKPQ
DMK Pharmaceuticals Corp
21 Dec 23
Termination of a Material Definitive Agreement
12:31pm
in the United States, and was responsible for marketing, promotion and distribution efforts. The distribution agreement between the Company and US WorldMeds
8-K
EX-99.1
DMKPQ
DMK Pharmaceuticals Corp
28 Nov 23
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
4:41pm
, and was responsible for marketing, promotion and distribution efforts.
The Company is now actively seeking out-license opportunities for SYMJEPI®
8-K
DMKPQ
DMK Pharmaceuticals Corp
28 Nov 23
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
4:41pm
for SYMJEPI and ZIMHI (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts. The distribution
8-K
EX-10.3
d8za0l9d7pow
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-10.4
wltd7wpem848 uqrrq
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
DEFC14A
pcwtifzu66soc
12 Oct 23
Proxy in contested solicitation
4:22pm
PREC14A
8n6w7bhhb8yvdwv
2 Oct 23
Preliminary proxy with contested solicitation
4:49pm
8-K
EX-1.1
pqzybr2
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
8-K
EX-10.1
u5b6lxc5pi4xr1m2
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
424B4
lypvk ijpgsb9
3 Aug 23
Prospectus supplement with pricing info
4:55pm
8-K
EX-10.2
r3uk7 mev
24 Jul 23
Entry into a Material Definitive Agreement
4:20pm